{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T11:59:55Z","timestamp":1768132795437,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-024-00832-9","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T11:00:42Z","timestamp":1740481242000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies"],"prefix":"10.1186","volume":"26","author":[{"given":"Mohammad Amin","family":"Karimi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanieh","family":"Norooziseyedhosseini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Khademi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Ghajary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haniyeh","family":"Kargar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyyedeh Sana","family":"Abdollahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohaddeseh","family":"Belbasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahdyieh","family":"Naziri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niloofar","family":"Deravi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajjad","family":"Hajihosseini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saharnaz","family":"Mofidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"832_CR1","doi-asserted-by":"publisher","first-page":"17648","DOI":"10.1038\/s41598-022-21546-0","volume":"12","author":"SA Alsagaby","year":"2022","unstructured":"Alsagaby SA, et al. In silico investigations identified Butyl Xanalterate to competently target CK2\u03b1 (CSNK2A1) for therapy of chronic lymphocytic leukemia. Sci Rep. 2022;12:17648.","journal-title":"Sci Rep"},{"key":"832_CR2","doi-asserted-by":"publisher","first-page":"1371057","DOI":"10.3389\/fonc.2024.1371057","volume":"14","author":"J Braish","year":"2024","unstructured":"Braish J, Cerchione C, Ferrajoli A. An overview of prognostic markers in patients with CLL. Front Oncol. 2024;14:1371057.","journal-title":"Front Oncol"},{"key":"832_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1182\/blood.2021010845","volume":"139","author":"P Langerbeins","year":"2022","unstructured":"Langerbeins P, et al. The CLL12 trial: ibrutinib vs placebo in treatment-na\u00efve, early-stage chronic lymphocytic leukemia. Blood. 2022;139:177\u201387.","journal-title":"Blood"},{"issue":"3","key":"832_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.blre.2015.12.002","volume":"30","author":"N Jain","year":"2016","unstructured":"Jain N, O\u2019Brien S. Targeted therapies for CLL: practical issues with the changing treatment paradigm. Blood Rev. 2016;30(3):233\u201344.","journal-title":"Blood Rev"},{"issue":"5","key":"832_CR5","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.3390\/cancers15051583","volume":"15","author":"P Iyer","year":"2023","unstructured":"Iyer P, Wang L. Emerging therapies in CLL in the era of precision medicine. Cancers (Basel). 2023;15(5):1583.","journal-title":"Cancers (Basel)"},{"key":"832_CR6","first-page":"37","volume":"8","author":"JC Chavez","year":"2013","unstructured":"Chavez JC, Sahakian E, Pinilla-Ibarz J. Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia. Core Evid. 2013;8:37\u201345.","journal-title":"Core Evid"},{"key":"832_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1756-8722-6-59","volume":"6","author":"A Akinleye","year":"2013","unstructured":"Akinleye A, et al. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol. 2013;6:59.","journal-title":"J Hematol Oncol"},{"key":"832_CR8","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","volume":"117","author":"SE Herman","year":"2011","unstructured":"Herman SE, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117:6287\u201396.","journal-title":"Blood"},{"key":"832_CR9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/phar.1366","volume":"34","author":"V Bhatt","year":"2014","unstructured":"Bhatt V, et al. The promising impact of ibrutinib, a Bruton\u2019s tyrosine kinase inhibitor, for the management of lymphoid malignancies. Pharmacotherapy. 2014;34:303\u201314.","journal-title":"Pharmacotherapy"},{"key":"832_CR10","doi-asserted-by":"publisher","first-page":"e985","DOI":"10.1016\/j.clml.2021.07.022","volume":"21","author":"P Abrisqueta","year":"2021","unstructured":"Abrisqueta P, et al. Real-world characteristics and outcome of patients treated with single-agent ibrutinib for chronic lymphocytic leukemia in Spain (IBRORS-LLC Study). Clin Lymphoma Myeloma Leuk. 2021;21:e985\u2013e999.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"832_CR11","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.3390\/cancers15051504","volume":"15","author":"AM Frustaci","year":"2023","unstructured":"Frustaci AM, et al. Next generation BTK inhibitors in CLL: evolving challenges and new opportunities. Cancers (Basel). 2023;15:1504.","journal-title":"Cancers (Basel)"},{"key":"832_CR12","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","volume":"6","author":"A Younes","year":"2019","unstructured":"Younes A, et al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study. Lancet Haematol. 2019;6:e67\u2013e78.","journal-title":"Lancet Haematol"},{"key":"832_CR13","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1080\/10428194.2020.1795159","volume":"61","author":"GA Fraser","year":"2020","unstructured":"Fraser GA, et al. Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma. Leuk Lymphoma. 2020;61:3188\u201397.","journal-title":"Leuk Lymphoma"},{"key":"832_CR14","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1200\/JCO.22.00510","volume":"41","author":"P Hillmen","year":"2023","unstructured":"Hillmen P, et al. Zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial. J Clin Oncol. 2023;41:1035.","journal-title":"J Clin Oncol"},{"key":"832_CR15","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/cam4.1337","volume":"7","author":"X Huang","year":"2018","unstructured":"Huang X, et al. Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study. Cancer Med 2018;7:1043\u201355.","journal-title":"Cancer Med"},{"key":"832_CR16","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1182\/blood.V124.21.3331.3331","volume":"124","author":"JR Brown","year":"2014","unstructured":"Brown JR, et al. Updated efficacy including genetic and clinical subgroup analysis and overall safety in the phase 3 RESONATETM trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma. Blood. 2014;124:3331.","journal-title":"Blood"},{"issue":"4","key":"832_CR17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.5045\/br.2020.2020158","volume":"55","author":"M G\u00f6\u00e7er","year":"2020","unstructured":"G\u00f6\u00e7er M, Kurto\u011flu E. Safety and efficacy analysis of ibrutinib in 32 patients with CLL and various B-cell lymphomas: real-world data from a single-center study in Turkey. Blood Res. 2020;55(4):206\u201312.","journal-title":"Blood Res"},{"key":"832_CR18","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.21873\/anticanres.14403","volume":"40","author":"B Pula","year":"2020","unstructured":"Pula B, et al. Long-term efficacy of ibrutinib in relapsed or refractory chronic lymphocytic leukemia: results of the polish adult leukemia study group observational study. Anticancer Res 2020;40:4059\u201366.","journal-title":"Anticancer Res"},{"key":"832_CR19","first-page":"5350","volume":"130","author":"OS Akhtar","year":"2017","unstructured":"Akhtar OS, et al. Disease progression on ibrutinib therapy is associated with a poor clinical outcome in chronic lymphocytic leukemia (CLL) patients managed in standard clinical practice. Blood. 2017;130:5350.","journal-title":"Blood"},{"key":"832_CR20","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41409-019-0742-7","volume":"55","author":"M Michallet","year":"2020","unstructured":"Michallet M, et al. Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia. Bone Marrow Transplant. 2020;55:884\u201390.","journal-title":"Bone Marrow Transplant"},{"key":"832_CR21","doi-asserted-by":"publisher","first-page":"5845","DOI":"10.3390\/jcm10245845","volume":"10","author":"A Broccoli","year":"2021","unstructured":"Broccoli A, et al. Long-term efficacy and safety of ibrutinib in the treatment of CLL patients: a real life experience. J Clin Med. 2021;10:5845.","journal-title":"J Clin Med"},{"key":"832_CR22","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1182\/bloodadvances.2022008821","volume":"7","author":"S Bonfiglio","year":"2023","unstructured":"Bonfiglio S, et al. BTK and PLCG2 remain unmutated in one third of patients with CLL relapsing on ibrutinib. Blood Adv. 2023;7:2794\u2013806.","journal-title":"Blood Adv"},{"key":"832_CR23","first-page":"2497","volume":"125","author":"JC Byrd","year":"2015","unstructured":"Byrd JC, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood J Am Soc Hematol. 2015;125:2497\u2013506.","journal-title":"Blood J Am Soc Hematol"},{"key":"832_CR24","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3960\/jslrt.22002","volume":"62","author":"A Omi","year":"2022","unstructured":"Omi A, et al. Efficacy and safety of ibrutinib in relapsed\/refractory CLL and SLL in Japan: a post-marketing surveillance. J Clin Exp Hematop. 2022;62:136\u201346.","journal-title":"J Clin Exp Hematop"},{"key":"832_CR25","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1182\/blood.V126.23.1745.1745","volume":"126","author":"L Hansson","year":"2015","unstructured":"Hansson L, et al. Real-world results on ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): data from 97 Swedish patients treated in a compassionate use program. Blood. 2015;126:1745.","journal-title":"Blood"},{"key":"832_CR26","first-page":"2915","volume":"125","author":"JR Brown","year":"2015","unstructured":"Brown JR, et al. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood J Am Soc Hematol. 2015;125:2915\u201322.","journal-title":"Blood J Am Soc Hematol"},{"key":"832_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood-2020-140622","volume":"136","author":"WG Wierda","year":"2020","unstructured":"Wierda WG, et al. Transcend CLL 004: phase 1 cohort of lisocabtagene maraleucel (liso-cel) in combination with ibrutinib for patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL). Blood. 2020;136:39\u201340.","journal-title":"Blood"},{"key":"832_CR28","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","volume":"15","author":"JA Burger","year":"2014","unstructured":"Burger JA, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014;15:1090\u201399.","journal-title":"Lancet Oncol"},{"key":"832_CR29","doi-asserted-by":"publisher","unstructured":"Brown, J.R., et al., Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388(4):319\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2211582","DOI":"10.1056\/NEJMoa2211582"},{"key":"832_CR30","doi-asserted-by":"publisher","unstructured":"Byrd, J.C., et al., Ibrutinib treatment for first-line and relapsed\/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib\/II PCYC-1102 study. Clin Cancer Res. 2020;26(15):3918\u201327. https:\/\/doi.org\/10.1158\/1078-0432.ccr-19-2856","DOI":"10.1158\/1078-0432.ccr-19-2856"},{"key":"832_CR31","doi-asserted-by":"publisher","unstructured":"Byrd, J.C., et al., Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39(31):3441\u201352. https:\/\/doi.org\/10.1200\/jco.21.01210","DOI":"10.1200\/jco.21.01210"},{"key":"832_CR32","doi-asserted-by":"publisher","unstructured":"Munir, T., et al., Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353\u201363. https:\/\/doi.org\/10.1002\/ajh.25638","DOI":"10.1002\/ajh.25638"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00832-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-024-00832-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00832-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T11:00:46Z","timestamp":1740481246000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-024-00832-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["832"],"URL":"https:\/\/doi.org\/10.1186\/s40360-024-00832-9","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"9 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}